Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke

Lancet

Volumn 350, Issue 9078, 1997, Pages 607-614

  Wardlaw, J M ^a,b   Warlow, C P ^a   Counsell, C ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CAUSE OF DEATH; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FIBRINOLYTIC THERAPY; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; STROKE; TIME; TREATMENT OUTCOME;

EID: 0030820028     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)03022-5     Document Type: Article

References (40)

1. Sussman BJ, Fitch TSP. Thrombolysis with fibrinolysin in cerebral arterial occlusion. JAMA 1958; 167: 1705-09.
2. Wardlaw JM, Warlow CP. Thrombolysis in acute ischaemic stroke: does it work? Stroke 1992; 23: 1826-39.
3. Hommel M, Cornu C, Boutitie F, Boissel JP. Multicentre Acute Stroke Trial Europe: thrombolytic therapy with streptokinase in acute ischaemic stroke. N Engl J Med 1996; 335: 145-50.
4. Donnan GA, Davis SM, Chambers BR, et al (Australian streptokinase trial investigators). Streptokinase in acute ischaemic stroke: does time of therapy administration affect outcome? JAMA 1996; 271: 961-66.
5. Multicentre Acute Stroke Trial: Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995; 346: 1509-14.
6. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: tissue plasminogen activator for acute ischaemic stroke. N Engl J Med 1995; 333: 1581-87.
7. European Cooperative Acute Stroke Study (ECASS). Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA 1995; 274: 1017-25.
8. Adams HP, Brott TG, Furlan AJ, et al. Guidelines for thrombolytic therapy for acute ischemic stroke: a statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. Circulation 1996; 94: 1167-74.
9. The European Ad Hoc Consensus Group. European strategies for early intervention in stroke. Cerebrovasc Dis 1996; 6: 315-24.
10. Muir K. Multicentre Acute Stroke Trial: Italy. Lancet 1996; 347: 391.
11. Shahar E, McGovern P. Trials of streptokinase in severe acute ischaemic stroke. Lancet 1995; 345: 578.
12. Peto R. Why do we need systematic reviews of randomised trials? Stat Med 1987; 6: 233-40.
13. Wardlaw JM, Yamaguchi T, del Zoppo GJ. The efficacy and safety of thrombolytic therapy in acute ischaemic stroke: a systematic review of the randomised trials comparing thrombolysis with control. In: Warlow CP, Van Gijn J, Sandercock P, eds. Stroke module of the Cochrane database of systematic reviews. Cochrane Library [CD ROM and on line]. Oxford: Update Software 1997: updated quarterly.
14. Haley EC, Brott TG, Sheppard GL, et al (for the tPA bridging study group). Pilot randomized trial of tissue plasminogen activator in acute ischaemic stroke. Stroke 1993; 24: 1000-04.
15. Morris AD, Ritchie C, Grosset DG, et al. A pilot study of streptokinase for acute cerebral infarction. Q J Med 1995; 88: 727-31.
16. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
17. Fibrinolytic Therapy Trialists' Collaboration. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-22.
18. Thomson SG. Controversies in metaanalysis: the case of the trials of serum cholesterol reduction. Stat Methods Med Res 1993; 2: 173-92.
19. Naito I, Abe T. Oral urokinase: absorption, mechanisms of fibrinolytic enhancement and clinical effect on cerebral thrombosis. Folia-Haematol (Leipz) 1986; 113: 122-36.
20. Wardlaw JM, Lindley RI, Warlow CP, Sandercock PAG. A pilot study of intra-arterial thrombolysis for acute ischaemic stroke. J Neurol Neurosurg Psychiatry 1994; 57: 251 (abstr).
21. Meyer JS, Gilroy J, Barnhart MI, Johnson JF. Therapeutic thrombolysis in cerebral thromboembolism. Neurology 1963; 13: 927-37.
22. Meyer JS, Gilroy J, Barnhart MI, Johnson JF. Anticoagulants plus streptokinase therapy in progressing stroke. JAMA 1964; 189: 373.
23. Pang Shi-qu, et al. Clinical study of therapeutic effectiveness in treating ischaemic cerebrovascular disease with lumbrokinase. Chin J Neurol Psychiatry 1993; 26: 229-31.
24. Wu he Xiang. Urokinase therapy in acute ischaemic stroke. In: Proc of the Fourth Chinese Stroke Conference, Chengdu, 1995: 149 (abstr).
25. Zhang Yuan Xiang. Thrombolytic therapy and external counterpulsation in acute cerebral infarction: proceedings of the Fourth Chinese Stroke Conference, Chengdu, 1995: 44 (abstr).
26. Davis SM, Donnan GA, Gerraty RP, et al. Australian Urokinase Stroke Trial. Cerebrovasc Dis 1996; 6: 188 (abstr).
27. Del Zoppo GJ, Higashida R, Furlan A, et al. The prolyse in acute cerebral thromboembolism trial (PROACT): results of 6 mg dose tier. Cerebrovasc Dis 1996; 6: 184 (abstr).
28. EMS Bridging Trial Investigators. Combined intravenous and intraarterial thrombolysis versus intraarterial thrombolysis alone: preliminary safety and clot lysis. Cerebrovasc Dis 1996; 6: 184 (abstr).
29. Abe T, Kazama M, Naito I, et al. Clinical evaluation for efficacy of tissue cultured urokinase (TCUK) on cerebral thrombosis by means of multi-centre double blind study. Blood-Vessel 1981; 12: 321-41.
30. Atarashi I, Ohtomo E, Araki G, Itoh E, Togi H, Matsuda T. Clinical utility of urokinase in the treatment of acute stage cerebral thrombosis: multi-center double blind study in comparison with placebo. Clin Eval 1985; 13: 659-709.
31. Ohtomo E, Araki G, Itoh E, et al. Clinical efficacy of urokinase in the treatment of cerebral thrombosis: multi-centre double-blind study in comparison with placebo. Clin Eval 1985; 15: 711-31.
32. Mori E, Yoneda Y, Tabuchi M, et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992; 42: 976-82.
33. Yamaguchi T, Japanese Thrombolysis Study Group. Intravenous tissue plasminogen activator in acute thromboembolic stroke: a placebo controlled, double blind trial. In: del Zoppo GJ, Mori E, Hacke W, eds. Thrombolytic therapy in acute ischaemic stroke II. New York: Springer Verlag, 1993: 59-65.
34. Motto C, Candelise L, Aritzu E, Ciccone A, Piaria A. On behalf of the MAST-I group: aspirin in combination with thrombolysis increases the risk of early death but not of intracerebral bleeding patients with acute ischaemic stroke. Cerebrovasc Dis 1996; 6 (suppl 2): 129 (abstr).
35. The MAST-Italy investigators. Predictions of good outcome in the MAST-Italy trial. Cerebrovasc Dis 1996; 6: 183 (abstr).
36. Sharp SJ, Thompson SG, Altman DG. The relation between treatment benefit and underlying risk in metaanalysis. BMJ 1996; 313: 735-38.
37. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997; 349: 1269-76.
38. Antman EM, Lau J, Kupelnick B, Mosteller F, Chalmers T. A comparison of results of meta-analyses of randomised controlled trials and recommendations of clinical experts. JAMA 1992; 268: 240-48.
39. International Stroke Trial Collaborative Group. A randomised trial of aspirin, subcutaneous heparin, both or neither among 19 436 patients with acute, presumed ischaemic stroke. Lancet 1997; 349: 1569-81.
40. Solomon NA, Glick HA, Russo CJ, Lee J, Schulman KA. Patient preferences for stroke outcomes. Stroke 1994; 25: 1721-25.